Pharmacy, Children's Hospital of Fudan University, Shanghai, China.
College of Pharmacy, Fudan University, Shanghai, China.
Pak J Pharm Sci. 2020 Mar;33(2):537-542.
Valproic acid (VPA) was a classic antiepileptic drug for fifty years. However, individual variability of plasma drug concentration was obvious in epilepsy patients and few researches focused on the relationship between concentration and efficacy. Consequently, in this study, the correlation of VPA concentration and efficacy was analyzed according to the subgroups of age, gender, and co-medication in Chinese children. Children diagnosed by epilepsy with monitoring of VPA from April 1, 2014 to March 31, 2017 were recruited. Data on age, gender, diagnosis, dose, co-medication, and concentration of VPA was collected and analyzed according to the efficacy. Total of 486 concentration data was included in this study. Doses and plasma concentrations were significantly increased with age (P<0.001, P<0.001). After adjusted by dose, the uncontrolled elder children (12-18 years) showed higher concentration/dose (C/D) ratio than the controlled group (P=0.02). However, there were no differences between male and female. For polytherapy, the C/D ratio of uncontrolled-group was higher than that of controlled group (P=0.005), especially with levetiracetam (LEV) and topiramate (TPM) (P=0.028, P=0.048). Age could explain some of the inter-individual pharmacokinetic of VPA, however, gender was not related to the concentration or efficacy of VPA which suggested that concentration monitoring was indispensable to children. Low metabolism, especially in the combination of LEV and TPM, might associate with the resistance of VPA, which could be a new sight to explore the resistance of VPA.
丙戊酸(VPA)作为经典的抗癫痫药物已有 50 年历史。然而,癫痫患者的血浆药物浓度个体差异明显,且少有研究关注浓度与疗效的关系。因此,本研究根据年龄、性别和合并用药亚组分析了中国儿童 VPA 浓度与疗效的关系。
本研究纳入了 2014 年 4 月 1 日至 2017 年 3 月 31 日接受 VPA 监测诊断为癫痫的儿童。收集并分析了年龄、性别、诊断、剂量、合并用药和 VPA 浓度等数据,根据疗效进行分组。
共纳入 486 个浓度数据。年龄与剂量和血浆浓度均呈显著正相关(P<0.001,P<0.001)。校正剂量后,年龄较大(12-18 岁)未控制组的浓度/剂量(C/D)比值高于控制组(P=0.02)。但男女之间无差异。对于联合用药,未控制组的 C/D 比值高于控制组(P=0.005),尤其是与左乙拉西坦(LEV)和托吡酯(TPM)联用时(P=0.028,P=0.048)。年龄可以解释 VPA 个体间药代动力学的一部分,但性别与 VPA 的浓度或疗效无关,这提示浓度监测对于儿童是不可或缺的。代谢率低,尤其是 LEV 和 TPM 联合用药时,可能与 VPA 的耐药性有关,这为探讨 VPA 的耐药性提供了新的思路。